[go: up one dir, main page]

AR070361A1 - Compuestos heterociclicos antiviricos - Google Patents

Compuestos heterociclicos antiviricos

Info

Publication number
AR070361A1
AR070361A1 ARP090100481A ARP090100481A AR070361A1 AR 070361 A1 AR070361 A1 AR 070361A1 AR P090100481 A ARP090100481 A AR P090100481A AR P090100481 A ARP090100481 A AR P090100481A AR 070361 A1 AR070361 A1 AR 070361A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
hydrogen
acyl
optionally substituted
Prior art date
Application number
ARP090100481A
Other languages
English (en)
Inventor
Francisco Xavier Talamas
Robert James Weikert
Clara Jeou Jen Lin
Sharada Shenvi Labadie
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40521706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR070361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR070361A1 publication Critical patent/AR070361A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Son inhibidores de la polimerasa NS5b del virus de la hepatitis C. Se describen también composiciones y métodos para tratar una infeccion del HCV y para inhibir la replicacion del HCV. Reivindicacion1: Un compuesto de la formula (1) en la que A1 es fenileno o piridinileno; A2 es fenilo o piridinilo opcionalmente sustituidos por 1-3 grupos elegidos con independencia entre el grupo formado por halogeno, alquilo C1-6, haloalquilo C1-6, ciano y alcoxi C1-6; R1 es hidrogeno, alquilo C1-10, cicloalquilo C3-7, alcoxi C1-10 o halogeno; Y es NR2R3, hidroxialquilo C1-6, acilo C1-6 o heteroarilo elegido entre el grupo formado por pirrolilo, pirazolilo o isoxazolilo, dicho heteroarilo está opcionalmente sustituido por uno o dos grupos elegidos entre alquilo C1-3, haloalquilo C1-3, alcoxi C1-3, halogeno o pirrolidinilo, en el que el átomo de nitrogeno está opcionalmente sustituido por acilo C1-6 o alquilsulfonilo C1-6; en la que (i) R2 es (a) hidrogeno, (b) alquilo C1-10, (c) alquilo C1-10 sustituido de una a cuatro veces por restos elegidos con independencia entre hidroxi, NR7bR8b, alcoxi C1-3, halogeno y ciano; (d) R11S(=O)m[C(R5)2]1-6 en el que R11 es alquilo C1-6 o NR7cR8c;8; (e) alquilo C1-3-S(=O)2NH-[C(R5)2]1-6; (f) R7bR8bNC(=O)-[C(R5)2]1-6; (g) cicloalquilo C3-6 opcionalmente sustituido por -OH, alcoxi C1-3 o -NR7bR8b; (h) heterociclilo; (i) heterociclil-alquilo C1-6, (j) heteroaril-alquilo C1-6, (k) acilo C1-6 opcionalmente sustituido por alquilsulfonilo C1-6; (l) (CH2)pCOX3 en el que p es un numero de uno a seis y X3 es hidroxi, alcoxi C1-6 o NR7cR8c; en el que dicho resto heterociclilo es oxetanilo, tetrahidrofuranilo, tetrahidropiranilo, azetidinilo, pirrolidinilo o piperidinilo, oxazolidin-2-on-4-ilo y dicho resto heteroarilo es piridinilo o pirimidinilo y dichos grupos heterociclilo o heteroarilo están opcionalmente sustituidos por -OH, alcoxi C1-3, alquilo C1-3 o -NR7bR8b; R3 es hidrogeno, alquilo C1-10, S(O)2R6, S(=O)2NR7aR8a, acilo C1-6 o C(=O)NR7aR8a; o bien (ii) R2 y R3 juntos son (CH2)2X1(CH2)2, (CH2)3-4S(=O)2, (CH2)2-3NR10S(=O)2; R4 y R5 son con independencia hidrogeno, alquilo C1-6 o cicloalquilo C3-7; R6 es alquilo C1-6 o cicloalquilo C3-7; R7a y R8a son (i) con independencia hidrogeno, alquilo C1-6, hidroxialquilo C1-6, haloalquilo C1-6 o bien (ii) R7a y R8a juntos son (CH2)2X1(CH2)2; R7b, R8b y R10 son con independencia hidrogeno, alquilo C1-6, acilo C1-6 o alquilsulfonilo C1-6, R7c y R8c son con independencia hidrogeno o alquilo C1-3; R9 es hidrogeno, acilo C1-3, alquilsulfonilo C1-3 o alquilo C1-3; R10 es hidrogeno o alquilo C1-6; X1 es -O-, -NR9-, -S(O)m, (CH2)n; X2 es NHR5 u O; m y n son con independencia un numero entero de 0 a 2; o, una sal farmacéuticamente aceptables del mismo.
ARP090100481A 2008-02-14 2009-02-12 Compuestos heterociclicos antiviricos AR070361A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2862908P 2008-02-14 2008-02-14
US13860308P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
AR070361A1 true AR070361A1 (es) 2010-03-31

Family

ID=40521706

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100481A AR070361A1 (es) 2008-02-14 2009-02-12 Compuestos heterociclicos antiviricos

Country Status (18)

Country Link
US (1) US8071797B2 (es)
EP (1) EP2245023B1 (es)
JP (1) JP2011512341A (es)
KR (1) KR20100117073A (es)
CN (1) CN101910145A (es)
AR (1) AR070361A1 (es)
AT (1) ATE539070T1 (es)
AU (1) AU2009214194B2 (es)
BR (1) BRPI0907885A2 (es)
CA (1) CA2714254A1 (es)
CL (1) CL2009000305A1 (es)
ES (1) ES2377280T3 (es)
IL (1) IL204736A0 (es)
MX (1) MX2010004623A (es)
PE (1) PE20091458A1 (es)
RU (1) RU2010137635A (es)
TW (1) TW200936573A (es)
WO (1) WO2009101022A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
KR20120079111A (ko) * 2009-09-24 2012-07-11 에프. 호프만-라 로슈 아게 헤테로환형 항바이러스성 화합물
US8324212B2 (en) 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN102906080A (zh) * 2010-03-11 2013-01-30 百时美施贵宝公司 治疗丙型肝炎的化合物
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
US8445497B2 (en) 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EA025151B1 (ru) 2010-10-26 2016-11-30 Пресидио Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
US8507683B2 (en) 2010-12-09 2013-08-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP5918264B2 (ja) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
US9119868B2 (en) * 2011-08-17 2015-09-01 Glaxosmithkline Llc Therapeutic methods
EP3199531A1 (en) * 2011-08-19 2017-08-02 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2831066B1 (en) 2012-03-27 2016-10-05 Bristol-Myers Squibb Company Benzofuran derivatives for the treatment of hepatitis c
US9434738B2 (en) 2013-01-10 2016-09-06 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis C
US8962651B2 (en) 2013-03-13 2015-02-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2014159559A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Fused furans for the treatment of hepatitis c
WO2015143256A1 (en) * 2014-03-21 2015-09-24 Bristol-Myers Squibb Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
EP3119786B1 (en) 2014-03-21 2018-08-01 Bristol-Myers Squibb Company 6h-furo[2,3-e]indole compounds for the treatment of hepatitis c
ES2688554T3 (es) 2014-03-21 2018-11-05 Bristol-Myers Squibb Company Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis C
ES2689278T3 (es) 2014-05-21 2018-11-13 Bristol-Myers Squibb Company Compuestos de 2-(aril o heteroaril)fenilo (aza)benzofurano para el tratamiento de la hepatitis C
EP3154963A1 (en) 2014-06-11 2017-04-19 Bristol-Myers Squibb Company Substituted 2-phenyl (aza)benzofuran compounds for the treatment of hepatitis c
EP3180346A1 (en) 2014-08-05 2017-06-21 Bristol-Myers Squibb Company Furopyridine compounds for the treatment of hepatitis c
JP2017529401A (ja) * 2014-09-26 2017-10-05 チャーンジョウ インシュヨン ファーマシューティカル カンパニー，リミティド Ｎｓ４ｂ阻害剤としてのベンゾフラン類似体
WO2016054299A1 (en) 2014-10-02 2016-04-07 Bristol-Myers Squibb Company Macrocyclic benzofuran compounds for the treatment of hepatitis c
US10125137B2 (en) 2015-02-19 2018-11-13 Bristol-Myers Squibb Company Benzofurans substituted with bicyclic secondary benzamide as HCV inhibitors
US10570108B2 (en) 2015-02-19 2020-02-25 Bristol-Myers Squibb Company Substituted benzofuran compounds for the treatment of hepatitis C
US10087167B2 (en) 2015-02-19 2018-10-02 Bristol-Myers Squibb Company Benzofurans substituted with secondary benzamide as HCV inhibitors
WO2016133970A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with primary benzamide as hcv inhibitors
WO2016133948A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofuran compounds for the treatment of hepatitis c
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
CN105732602B (zh) * 2015-09-23 2017-04-19 常州寅盛药业有限公司 作为ns4b抑制剂的苯并呋喃类似物
JP6828229B2 (ja) * 2015-11-19 2021-02-10 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ベンゾフラン誘導体、その製造方法および医薬におけるその使用
KR20210084681A (ko) 2015-11-24 2021-07-07 로레알 모발 처리를 위한 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0315937A (pt) * 2002-11-01 2005-09-13 Viropharma Inc Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo
AR059430A1 (es) * 2006-02-09 2008-04-09 Schering Corp Novedosas combinaciones y metodos de inhibidores del vhc
AU2008216382A1 (en) * 2007-02-12 2008-08-21 Array Biopharma, Inc. Novel inhibitors hepatitis C virus replication

Also Published As

Publication number Publication date
ES2377280T3 (es) 2012-03-26
JP2011512341A (ja) 2011-04-21
ATE539070T1 (de) 2012-01-15
EP2245023B1 (en) 2011-12-28
RU2010137635A (ru) 2012-03-20
CA2714254A1 (en) 2009-08-20
AU2009214194B2 (en) 2012-05-17
CN101910145A (zh) 2010-12-08
BRPI0907885A2 (pt) 2015-07-21
CL2009000305A1 (es) 2010-02-19
TW200936573A (en) 2009-09-01
PE20091458A1 (es) 2009-09-24
EP2245023A1 (en) 2010-11-03
MX2010004623A (es) 2010-06-07
US8071797B2 (en) 2011-12-06
US20090208449A1 (en) 2009-08-20
WO2009101022A1 (en) 2009-08-20
KR20100117073A (ko) 2010-11-02
IL204736A0 (en) 2010-11-30
AU2009214194A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
AR070361A1 (es) Compuestos heterociclicos antiviricos
AR064221A1 (es) Inhibidores no nucleosidos de transcriptasa inversa
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR062928A1 (es) Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
AR068935A1 (es) Derivados heterociclicos de piridina, pirimidina y piridazina oxo-sustituidas, inhibidores de quinasas
PE20091381A1 (es) Inhibidores del virus de la hepatitis c
NO20081074L (no) Macrocyclisk inhibitorer av hepatitis C-virus
NO20080875L (no) Nye makrocykliske inhibitorer av hepatitt C virus replikasjon
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
UY30387A1 (es) Nuevos compuestos
AR078397A1 (es) Compuestos heterociclicos antivirales
ATE512954T1 (de) Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine
NO20080879L (no) HCV-NS3-proteaseinhibitorer
ATE547103T1 (de) Hemmer des hepatitis-c-virus
AR082696A1 (es) Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
CO6180424A2 (es) Inhibodores espiro cetona de acetil-coa carboxilasa
AR059571A1 (es) Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas
CO6361916A2 (es) Compuestos de isoindolina para uso en el tratamiento
AR086290A1 (es) Inhibidores del virus de la hepatitis c
AR047536A1 (es) Moduladores del receptor de quimioquina ccr5
AR061548A1 (es) 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii.
AR083070A1 (es) Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc

Legal Events

Date Code Title Description
FA Abandonment or withdrawal